Listed

Fate Therapeutics Inc: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on May 13, 2025 and accepted by EDGAR at May 13, 2025, 16:03 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-01-01 to 2025-03-31$1.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2025-01-01 to 2025-03-31$29.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2025-01-01 to 2025-03-31−$41.3mus-gaap:OperatingIncomeLoss
Net income3 months2025-01-01 to 2025-03-31−$37.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31−$0.32us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31−$0.32us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-01-01 to 2025-03-31118,375,540 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2025-01-01 to 2025-03-31−$33.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-01-01 to 2025-03-31$1.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-03-31$44.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$248.2mus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$398.7mus-gaap:Assets
Current liabilitiesAt period end2025-03-31$28.2mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2025-03-31$288.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-25-070285. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.